Back, abdominal, or stomach pain an adverse change in vision, coughing, shortness of breath, troubled breathing, tightness in the chest, or wheezing, discharge from the eye, dizziness, eye or eyelid pain, swelling, discomfort, or irritation, increased blood pressure, increased frequency of urination or painful urination, itching of the eyelid, seeing flashes or sparks of light, seeing floating spots before the eyes, swelling of lining of the eyelid, tiny bumps on lining of the eyelid, blistering, peeling, or loosening of the skin, blood in the urine, blue lips, fingernails, or skin, chest pain or discomfort, chills, cough, diarrhoea, difficult or troubled breathing, fainting, headache or weakness, severe and sudden, irregular, fast or slow, or shallow breathing, itching, joint or muscle pain, light-headedness, mental depression, nausea or vomiting, pain, numbness, tingling, or burning feeling in the hands or feet, red, irritated eyes, red skin lesions, often with a purple center, shortness of breath, skin rash,, slow or irregular heartbeat, sore throat, sores, ulcers, or white spots in the mouth or on the lips, sweating, unusual tiredness or weakness, cold- or flu-like symptoms, crusting or scales on eyelid, dryness of the eyes, indigestion or an upset stomach, a sore throat, a stuffy or runny nose, tearing of the eye, a burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feelings, depression, a dry mouth and/ or a stuffy nose.
For most patients in whom a nonselective nonsteroidal antiinflammatory drug (NSAID) is chosen for short-term (no more than a month) or intermittent use, we prescribe naproxen, rather than other NSAIDs. Other nonselective NSAIDs (eg, ibuprofen) are reasonable alternatives, given the low baseline risk in such patients and lack of evidence regarding the cardiovascular risks of occasional low-dose use. Nonselective NSAIDs should be used at the lowest effective dose and for the shortest duration required in order to limit adverse events. We also prefer naproxen to other nonselective NSAIDs for patients who require long-term (over a month) use.
On 5 November 2015, the . FDA held a joint meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss risks and benefits of the systemic fluoroquinolone antibacterial drugs for the acute bacterial sinusitis, acute bacterial exacerbations of bronchitis in people with chronic obstructive pulmonary disease, and uncomplicated urinary tract infections. The . FDA asked the committee to review reports of tendonitis and tendon rupture, peripheral neuropathy, and cardiac arrhythmia associated with long-term disability to determine whether the benefits of fluoroquinolone therapy in these indications justifies the associated risk.  The 21-member joint committee overwhelmingly recommended stronger label warnings on the containers because of rare but sometimes devastating side effects.